BackgroundWith the help of some antibodies CD43 has also been localized on non-haematopoietic tumours (melanoma, mamma carcinoma, and ovarian carcinoma), but the main purpose of MT1 antibody is the typing of T-cell lymphoma in tissue sections and bone marrow cell smears. CD43 (or Leukosialin) is a membrane sialoglycoprotein, which is expressed by all thymocytes and T-cells. It is also found on granulocytes, monocytes, macrophages, NK-cells, platelets, activated B-cells, plasma cells and haematopoietic stem cells. Normal B-cells don't express CD43. CD43 possibly interacts with CD54 (ICAM-1) and causes antigen specific T-cell activation. Human CD43 (95-160 kDa sialoglycoprotein) MW depending of cell type.

ProductAntibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGOArt .No. PU002.

Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGOArt .No. PU002.

Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).

Specificity

Species Reactivity: Human

ApplicationsIHC(P)

Incubation Time: 60 min at RT

Working Concentration: (liquid conc.) 1:10 - 1:20

Pre-Treatment: Pre-treatment with unmasking fluids E (Art. No. DE006) or C (Art. No. DE000).

Positive Control: Lymph node, tonsil

Storage2-8°C

Caution*These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals. ** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!

References1. Remold-O'Donnell E.,Parkman R., Cairns L., Savage B., and Rosen F.S. Characterization of a human leukocyte surface sialoglykoprotein that is defective in Wiskott-Aldrich syndrome. J. Exp. Med. 159; 1705-1723. 2. Poppema S. et al. (1987) Monoclonal antibodies (MT1, MT2, MB1, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections. Am. J. Pathol. 127,3; 418-429. 3. Stross, W.P., Flavell D.J., Flavell S.U., Simmons D., Gatter K.C., et al. (1989) Epitope specificity and staining properties of CD43 (sialophorin) antibodies. In Leucocyte Typing IV, Ed. W. Kapp et al. Oxford University Press 1989; pp 615-617. 4. Remold-O'Donnell E. (1995) CD43 cluster report. In Leucocyte Typing V, Schlossman S.F. et al. Eds. Oxford University Press 1995 pp.1697-1701.